An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses.
El Garch H, Crafford JE, Amouyal P, Durand PY, Edlund Toulemonde C, Lemaitre L, Cozette V, Guthrie A, Minke JM.
El Garch H, et al. Among authors: guthrie a.
Vet Immunol Immunopathol. 2012 Sep 15;149(1-2):76-85. doi: 10.1016/j.vetimm.2012.06.009. Epub 2012 Jun 15.
Vet Immunol Immunopathol. 2012.
PMID: 22763149
Clinical Trial.
A recombinant canarypox virus vectored vaccine co-expressing synthetic genes encoding outer capsid proteins, VP2 and VP5, of African horse sickness virus (AHSV) serotype 4 (ALVAC()-AHSV4) has been demonstrated to fully protect horses against homologous challenge with virul …
A recombinant canarypox virus vectored vaccine co-expressing synthetic genes encoding outer capsid proteins, VP2 and VP5, of African …